Monopar Therapeutics Inc. Earnings Per Share (Basic)
Monopar Therapeutics Inc. (MNPR) reported Earnings Per Share (Basic) of -$0.62 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Monopar Therapeutics Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.62.
- Monopar Therapeutics Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.46.
- Monopar Therapeutics Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.61.
- Monopar Therapeutics Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.48.
- Monopar Therapeutics Inc. earnings per share, basic for fiscal 2025 was -$1.85.
- Monopar Therapeutics Inc. earnings per share, basic for fiscal 2024 was -$4.11.
- Monopar Therapeutics Inc. earnings per share, basic for fiscal 2023 was -$3.04.
- Monopar Therapeutics Inc. earnings per share, basic for fiscal 2022 was -$0.83.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.62 10-Q · filed 2026-08-12 | -$1.08 10-Q · filed 2026-08-12 | -$1.69 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2026-03-31 | -$0.46 10-Q · filed 2026-05-14 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.92 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-12-31 | -$0.61 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.10 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.47 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.85 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$0.48 10-Q · filed 2025-11-13 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.21 10-Q · filed 2025-11-13 | -$2.99 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-06-30 | -$0.35 10-Q · filed 2026-08-12 | -$0.73 10-Q · filed 2026-08-12 | -$2.54 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.09 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2025-03-31 | -$0.38 10-Q · filed 2026-05-14 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.50 derived: net income ÷ weighted average shares · filed 2026-08-12 | ||||
| 2024-12-31 | -$2.23 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.90 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.51 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$4.11 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$0.37 10-Q · filed 2025-11-13 | -$0.86 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$1.36 10-Q · filed 2025-11-13 | -$1.97 derived: net income ÷ weighted average shares · filed 2026-04-30 | ||||
| 2024-06-30 | -$0.49 10-Q · filed 2025-08-12 | -$0.10 10-Q · filed 2024-08-09 | -$1.00 10-Q · filed 2025-08-12 | -$0.20 10-Q · filed 2024-08-09 | -$1.61 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.29 derived: net income ÷ weighted average shares · filed 2026-04-30 | ||
| 2024-03-31 | -$0.51 10-Q · filed 2025-05-13 | -$0.10 10-Q · filed 2024-05-09 | -$1.13 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.81 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-04-30 | |||
| 2023-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.31 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.04 10-K · filed 2025-03-31 | -$0.61 10-K · filed 2024-03-28 | |||
| 2023-09-30 | -$0.69 10-Q · filed 2024-11-08 | -$0.14 10-Q · filed 2023-11-09 | -$0.51 derived: net income ÷ weighted average shares · filed 2024-11-08 | -$2.43 10-Q · filed 2024-11-08 | -$0.49 10-Q · filed 2023-11-09 | -$0.90 derived: net income ÷ weighted average shares · filed 2024-11-08 | ||
| 2023-06-30 | -$0.16 10-Q · filed 2024-08-09 | -$0.35 10-Q · filed 2024-08-09 | -$0.57 derived: net income ÷ weighted average shares · filed 2024-11-08 | -$0.76 derived: net income ÷ weighted average shares · filed 2024-11-08 | ||||
| 2023-03-31 | -$0.19 10-Q · filed 2024-05-09 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-11-08 | -$0.60 derived: net income ÷ weighted average shares · filed 2024-11-08 | -$0.82 derived: net income ÷ weighted average shares · filed 2024-11-08 | ||||
| 2022-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.41 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.63 derived: net income ÷ weighted average shares · filed 2024-03-28 | -$0.83 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | -$0.19 10-Q · filed 2023-11-09 | -$0.41 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.60 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | -$0.22 10-Q · filed 2023-08-10 | -$0.41 10-Q · filed 2023-08-10 | ||||||
| 2021-12-31 | -$0.73 derived: net income ÷ weighted average shares · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |